US Bancorp’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.43M Buy
10,103
+8,132
+413% +$1.78M ﹤0.01% 854
2026
Q1
$373K Sell
1,971
-989
-33% -$173K ﹤0.01% 1657
2025
Q4
$503K Sell
2,960
-323
-10% -$49.5K ﹤0.01% 1530
2025
Q3
$433K Buy
3,283
+1,730
+111% +$208K ﹤0.01% 1595
2025
Q2
$165K Sell
1,553
-809
-34% -$87.9K ﹤0.01% 2152
2025
Q1
$293K Sell
2,362
-39
-2% -$5.09K ﹤0.01% 1800
2024
Q4
$296K Buy
2,401
+38
+2% +$4.48K ﹤0.01% 1807
2024
Q3
$263K Sell
2,363
-69
-3% -$7.56K ﹤0.01% 1887
2024
Q2
$260K Buy
2,432
+847
+53% +$93.1K ﹤0.01% 1855
2024
Q1
$191K Sell
1,585
-57
-3% -$6.98K ﹤0.01% 2035
2023
Q4
$202K Sell
1,642
-100
-6% -$12.5K ﹤0.01% 2004
2023
Q3
$225K Sell
1,742
-1
-0.1% -$133 ﹤0.01% 1777
2023
Q2
$216K Sell
1,743
-180
-9% -$24.2K ﹤0.01% 1831
2023
Q1
$281K Sell
1,923
-52
-3% -$7.69K ﹤0.01% 1708
2022
Q4
$315K Buy
1,975
+310
+19% +$45.4K ﹤0.01% 1625
2022
Q3
$222K Sell
1,665
-292
-15% -$44.4K ﹤0.01% 1789
2022
Q2
$305K Sell
1,957
-779
-28% -$120K ﹤0.01% 1688
2022
Q1
$427K Buy
2,736
+322
+13% +$46.7K ﹤0.01% 1602
2021
Q4
$308K Sell
2,414
-300
-11% -$39.4K ﹤0.01% 1776
2021
Q3
$353K Sell
2,714
-634
-19% -$95.8K ﹤0.01% 1691
2021
Q2
$595K Sell
3,348
-880
-21% -$152K ﹤0.01% 1454
2021
Q1
$695K Buy
4,228
+370
+10% +$60.9K ﹤0.01% 1332
2020
Q4
$638K Sell
3,858
-2,429
-39% -$362K ﹤0.01% 1322
2020
Q3
$896K Sell
6,287
-12,204
-66% -$1.51M ﹤0.01% 1050
2020
Q2
$2.04M Buy
18,491
+946
+5% +$105K 0.01% 713
2020
Q1
$1.75M Buy
17,545
+2,705
+18% +$350K 0.01% 707
2019
Q4
$2.21M Sell
14,840
-2,505
-14% -$341K 0.01% 742
2019
Q3
$2.22M Buy
17,345
+1,077
+7% +$144K 0.01% 726
2019
Q2
$2.32M Buy
16,268
+1,444
+10% +$194K 0.01% 724
2019
Q1
$2.12M Buy
14,824
+957
+7% +$125K 0.01% 743
2018
Q4
$1.72M Sell
13,867
-1,779
-11% -$264K 0.01% 791
2018
Q3
$2.63M Buy
15,646
+3,946
+34% +$679K 0.01% 706
2018
Q2
$2.02M Buy
11,700
+10,547
+915% +$1.72M 0.01% 800
2018
Q1
$175K Buy
1,153
+66
+6% +$9.68K ﹤0.01% 1938
2017
Q4
$147K Buy
1,087
+360
+50% +$49.9K ﹤0.01% 2055
2017
Q3
$107K Sell
727
-31
-4% -$4.69K ﹤0.01% 2189
2017
Q2
$118K Buy
758
+368
+94% +$56.3K ﹤0.01% 2109
2017
Q1
$56K Sell
390
-38
-9% -$4.95K ﹤0.01% 2428
2016
Q4
$46K Sell
428
-679
-61% -$75.6K ﹤0.01% 2485
2016
Q3
$135K Sell
1,107
-399
-26% -$53.8K ﹤0.01% 1937
2016
Q2
$213K Buy
1,506
+694
+85% +$102K ﹤0.01% 1695
2016
Q1
$106K Sell
812
-1,004
-55% -$125K ﹤0.01% 1978
2015
Q4
$256K Sell
1,816
-1,455
-44% -$202K ﹤0.01% 1588
2015
Q3
$434K Sell
3,271
-86
-3% -$14.8K ﹤0.01% 1355
2015
Q2
$591K Sell
3,357
-76
-2% -$13.6K ﹤0.01% 1273
2015
Q1
$594K Sell
3,433
-247
-7% -$42.4K ﹤0.01% 1279
2014
Q4
$603K Sell
3,680
-1,305
-26% -$217K ﹤0.01% 1244
2014
Q3
$801K Buy
4,985
+1,375
+38% +$211K ﹤0.01% 1077
2014
Q2
$531K Buy
3,610
+1,329
+58% +$184K ﹤0.01% 1315
2014
Q1
$316K Sell
2,281
-1,571
-41% -$236K ﹤0.01% 1547
2013
Q4
$488K Buy
3,852
+1,024
+36% +$106K ﹤0.01% 1316
2013
Q3
$260K Buy
2,828
+1,246
+79% +$101K ﹤0.01% 1551
2013
Q2
$109K Buy
+1,582
New +$96.7K ﹤0.01% 1974

Other funds holding JAZZ

US Bancorp's JAZZ Position: Q2 2026 in Review

US Bancorp increased its Jazz Pharmaceuticals (JAZZ) stake by 413% in Q2 2026, buying an estimated $1.78M and bringing the position to 10,103 shares worth $2.43M. The position accounts for ﹤0.01% of the portfolio, ranked #854.

US Bancorp first reported a position in JAZZ in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.63M in Q3 2018. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • US Bancorp held 10,103 shares of Jazz Pharmaceuticals worth $2.43M as of Q2 2026.
  • US Bancorp bought 8,132 Jazz Pharmaceuticals shares in Q2 2026, an estimated $1.78M.
  • Jazz Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #854 holding.
  • US Bancorp first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • US Bancorp's Jazz Pharmaceuticals position peaked at $2.63M in Q3 2018.
  • 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.